Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

559 ARTÍCULOS , VIENDO DEL 271 AL 285

Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer's disease: a randomized phase 1 study

Peng D, Xu S, Zou T, Wang Y, Ouyang W, Zhang Y, Dong C, Li D, Guo J, Shen Q, Hu X, Zhou W, Li X, Qin Q.

BMC Med. 2023 Nov 23;21(1):459. doi: 10.1186/s12916-023-03126-9.

Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms

Vuic B, Milos T, Tudor L, Nikolac Perkovic M, Konjevod M, Nedic Erjavec G, Farkas V, Uzun S, Mimica N, Svob Strac D.

Genes (Basel). 2023 Nov 6;14(11):2048. doi: 10.3390/genes14112048.

TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease

Shulman M, Kong J, O'Gorman J, Ratti E, Rajagovindan R, Viollet L, Huang E, Sharma S, Racine AM, Czerkowicz J, Graham D, Li Y, Hering H, Haeberlein SB.

Nat Aging. 2023 Dec;3(12):1591-1601. doi: 10.1038/s43587-023-00523-w. Epub 2023 Nov 27.

Alzheimer Disease: A New Beginning in Therapeutics

Honig LS.

Alzheimer Dis Assoc Disord. 2023 Oct-Dec 01;37(4):267-269. doi: 10.1097/WAD.0000000000000592. Epub 2023 Nov 28.

Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer's Disease

Rajput S, Malviya R, Bahadur S, Puri D.

Curr Pharm Des. 2023;29(35):2802-2813. doi: 10.2174/0113816128274618231105173031.

[Beneficial effects of ketogenic diet for Alzheimer's disease management]

Charlot A, Lernould A, Plus I, Zoll J.

Biol Aujourdhui. 2023;217(3-4):253-263. doi: 10.1051/jbio/2023031. Epub 2023 Nov 29.

The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer's Disease

Yan H, Feng L, Li M.

Drug Des Devel Ther. 2023 Nov 13;17:3295-3323. doi: 10.2147/DDDT.S380612. eCollection 2023.

Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease

Marei HE, Khan MUA, Hasan A.

Cell Mol Biol Lett. 2023 Nov 30;28(1):98. doi: 10.1186/s11658-023-00504-2.

A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease

Kashif M, Sivaprakasam P, Vijendra P, Waseem M, Pandurangan AK.

Curr Pharm Des. 2023;29(43):3428-3441. doi: 10.2174/0113816128264355231121064704.

Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resveratrol in the Treatment of Alzheimer's Disease

Jin S, Guan X, Min D.

Curr Alzheimer Res. 2023;20(8):588-602. doi: 10.2174/0115672050272577231120060909.

Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease

Shukla AK, Misra S.

J Basic Clin Physiol Pharmacol. 2023 Dec 6;35(1-2):25-29. doi: 10.1515/jbcpp-2023-0176. eCollection 2024 Jan 1.

The effect of light therapy on sleep disorders and psychobehavioral symptoms in patients with Alzheimer's disease: A meta-analysis

Zang L, Liu X, Li Y, Liu J, Lu Q, Zhang Y, Meng Q.

PLoS One. 2023 Dec 6;18(12):e0293977. doi: 10.1371/journal.pone.0293977. eCollection 2023.

Visualization analysis of exercise intervention on Alzheimer disease based on bibliometrics: Trends, hotspots and topics

Jin Y, Li X, Yuan Q, Huang X, Zhang D.

Medicine (Baltimore). 2023 Dec 8;102(49):e36347. doi: 10.1097/MD.0000000000036347.

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease

Lannfelt L.

Ups J Med Sci. 2023 Nov 28;128. doi: 10.48101/ujms.v128.10316. eCollection 2023.

Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment

Ashraf DA, Tariq H, Hassan FS, Kamran F, Khosa WM, Khosa MM.

Neurodegener Dis Manag. 2023 Oct;13(5):257-259. doi: 10.2217/nmt-2023-0026. Epub 2023 Dec 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias